$520M EV cancer testing co with a path to $100M EBIT in 2029 from a product that is less than 1% of their sales today. Deeply underestimated, $PSNL has the potential to 4x from here in short order.
$PSNL: Cancer Diagnostic Company On the Cusp…
$520M EV cancer testing co with a path to $100M EBIT in 2029 from a product that is less than 1% of their sales today. Deeply underestimated, $PSNL has the potential to 4x from here in short order.